Medipharm Labs Corp
TSX:LABS
Medipharm Labs Corp
Capital Expenditures
Medipharm Labs Corp
Capital Expenditures Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Capital Expenditures | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Medipharm Labs Corp
TSX:LABS
|
Capital Expenditures
-CA$161k
|
CAGR 3-Years
34%
|
CAGR 5-Years
64%
|
CAGR 10-Years
N/A
|
|
|
Bausch Health Companies Inc
TSX:BHC
|
Capital Expenditures
-$402m
|
CAGR 3-Years
-15%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
1%
|
|
|
Canopy Growth Corp
TSX:WEED
|
Capital Expenditures
-CA$8.8m
|
CAGR 3-Years
33%
|
CAGR 5-Years
56%
|
CAGR 10-Years
0%
|
|
|
Sundial Growers Inc
NASDAQ:SNDL
|
Capital Expenditures
-CA$11.1m
|
CAGR 3-Years
-19%
|
CAGR 5-Years
32%
|
CAGR 10-Years
N/A
|
|
|
Cronos Group Inc
TSX:CRON
|
Capital Expenditures
-$29.4m
|
CAGR 3-Years
-73%
|
CAGR 5-Years
3%
|
CAGR 10-Years
-37%
|
|
|
K
|
Knight Therapeutics Inc
TSX:GUD
|
Capital Expenditures
-CA$31.9m
|
CAGR 3-Years
-10%
|
CAGR 5-Years
-16%
|
CAGR 10-Years
-124%
|
|
Medipharm Labs Corp
Glance View
MediPharm Labs Corp. is medicinal cannabis company, which engages in the pharmaceutical grade production of cannabis oil products. The company is headquartered in Barrie, Ontario and currently employs 190 full-time employees. The company went IPO on 2018-02-09. The firm produces purified, pharmaceutical-like cannabis extracts and related derivative products. The firm formulates, processes, packages and distributes cannabis extracts and cannabinoid-based products at its Canadian and Australian facilities for domestic and international markets. The Company, through its subsidiaries is engaged in the sale and distribution of cannabis oil, cannabis extracts, cannabis edibles, cannabis topicals, and derivatives to authorized classes of purchasers, as well as controlled human administration trials for sensory testing of cannabis extracts and derivative products. The company is also engaged in the manufacturing of extracts and tinctures of cannabis and cannabis resin for the purpose of a clinical trial or prescribed as medical cannabis products. The firm's wholly owned subsidiaries include MediPharm Labs Inc. and MediPharm Labs Australia Pty. Ltd.
See Also
What is Medipharm Labs Corp's Capital Expenditures?
Capital Expenditures
-161k
CAD
Based on the financial report for Jun 30, 2025, Medipharm Labs Corp's Capital Expenditures amounts to -161k CAD.
What is Medipharm Labs Corp's Capital Expenditures growth rate?
Capital Expenditures CAGR 5Y
64%
Over the last year, the Capital Expenditures growth was 65%. The average annual Capital Expenditures growth rates for Medipharm Labs Corp have been 34% over the past three years , 64% over the past five years .
You don't have any saved screeners yet